Raymond Stadiem, MD
Endocrinology, Diabetes & Metabolism · Charlotte, NCNPI 1639332182
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,569 of the $31,749 with a category attached, or 86.8%. Sanofi-aventis U.S. LLC accounts for 71.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $13,655 and has fallen 98.4% since, to $215 in 2025.
Across 56 payments — averaging $566.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$23K
- Cequr Corporation$4K
- Lilly USA, LLC$3K
- Mannkind Corporation$2K
- Amgen$142
- Takeda Pharmaceuticals U.S.A., Inc.$125
- plus $160 from 4 others
What the payments were for
- Consulting fees$1,2754%
- Speaking & faculty fees$27,56987%
- Travel & lodging$6912%
- Food & beverage$2,0456%
- Gifts$1190%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 27 | $22,830 |
| Cequr Corporation | 5 | $3,556 |
| Lilly USA, LLC | 5 | $3,088 |
| Mannkind Corporation | 11 | $1,849 |
| Amgen(2 entities) | 2 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Abbott | 2 | $70 |
| Insulet Corporation | 1 | $48 |
| Amphastar Pharmaceuticals, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$15,058
- TOUJEO$7,418
- CeQur Simplicity$3,456
- BAQSIMI$3,088
- AFREZZA$1,512
- TEPEZZA$126
- NATPARA (PARATHYROID HORMONE)$125
How this compares
$31,749 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 264 | $382,382 |
| JardianceEmpagliflozin | 107 | $123,921 |
| MounjaroTirzepatide | 74 | $117,786 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 80 | $100,351 |
| TrulicityDulaglutide | 42 | $68,059 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 33 | $61,025 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $52,398 |
| JanuviaSitagliptin Phosphate | 26 | $41,151 |
| FarxigaDapagliflozin Propanediol | 45 | $37,798 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $34,823 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $34,278 |
| RybelsusSemaglutide | 25 | $30,363 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $26,007 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $24,244 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $22,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $3,088 | $190,618144 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $22,830 | $100,35180 claims |
| Cequr CorporationCequr Simplicity | $3,556 | $17,69834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Charlotte
- Charles UpchurchCharlotte$343K
- Adam SpitzCharlotte$33K
- Nisha NathanCharlotte$31K
- David BrantleyCharlotte$27K
- Kanakasabai NarasimhanCharlotte$25K
- Elizabeth HarrisCharlotte$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.